Key Points
- CEO Renée Galá sold 1,000 Jazz Pharmaceuticals shares for $225.37 each, totaling $225,370. The sale was made under a pre-arranged Rule 10b5-1 plan; she retained 140,394 shares.
- Jazz beat third-quarter estimates, posting $1.24 billion in revenue versus forecasts of $1.21 billion, with revenue up 10.4% year over year. The article also reports a raised 2026 revenue outlook of approximately $4.78 billion–$4.85 billion.
- Analysts’ consensus rating is Moderate Buy, with a consensus price target of $293.45.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CEO Renee Gala sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $225.37, for a total transaction of $225,370.00. Following the transaction, the chief executive officer directly owned 140,394 shares in the company, valued at approximately $31,640,595.78. The trade was a 0.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Stock Performance
Shares of NASDAQ:JAZZ opened at $227.32 on Friday. The company has a market capitalization of $14.59 billion, a price-to-earnings ratio of 77.32, a price-to-earnings-growth ratio of 0.47 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 52 week low of $128.80 and a 52 week high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. The firm has a 50 day moving average of $229.71 and a 200 day moving average of $217.40.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping analysts' consensus estimates of ($4.03) by $0.15. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. Jazz Pharmaceuticals's revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $8.13 earnings per share. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Jazz Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of JAZZ. Triumph Capital Management lifted its holdings in shares of Jazz Pharmaceuticals by 2.0% during the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company's stock valued at $626,000 after purchasing an additional 52 shares during the last quarter. Keybank National Association OH boosted its position in shares of Jazz Pharmaceuticals by 0.6% in the 3rd quarter. Keybank National Association OH now owns 10,141 shares of the specialty pharmaceutical company's stock worth $2,348,000 after purchasing an additional 57 shares in the last quarter. XML Financial LLC boosted its position in shares of Jazz Pharmaceuticals by 1.1% in the 3rd quarter. XML Financial LLC now owns 6,559 shares of the specialty pharmaceutical company's stock worth $1,519,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. grew its stake in Jazz Pharmaceuticals by 0.3% during the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company's stock worth $4,228,000 after buying an additional 73 shares during the last quarter. Finally, Root Financial Partners LLC grew its stake in Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company's stock worth $56,000 after buying an additional 89 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.
Trending Headlines about Jazz Pharmaceuticals
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
- Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
- Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing
Analysts Set New Price Targets
JAZZ has been the subject of a number of analyst reports. Citigroup initiated coverage on Jazz Pharmaceuticals in a research note on Wednesday, September 30th. They set a "buy" rating and a $325.00 price objective for the company. Canaccord Genuity Group set a $300.00 target price on Jazz Pharmaceuticals in a research note on Wednesday, August 26th. TD Cowen lifted their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a "buy" rating in a report on Wednesday, August 26th. Finally, Barclays increased their price target on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an "overweight" rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $293.45.
Check Out Our Latest Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
